VC-backed ProQR files for $75m IPO

Sofinnova is currently one of ProQR's biggest shareholders with a 17.2% stake, while Gilde holds a 5.3% stake. The two firms backed the business earlier this year, according to Gilde's website.

ProQR has hired Leerink Partners and Deutsche Bank Securities as lead bookrunners for the flotation.

Founded in 2012 and headquartered in Leiden, ProQR develops drugs designed for the treatment of genetic disorders. It is currently working on a treatment for cystic fibrosis. The company employs 50 staff.

Daniel de Boer is the CEO of ProQR. Gilde partner Arthur Franken manages the firm's investment in the company. Managing partner Antoine Papiernik represents Sofinnova.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Healthcare
• Sofinnova Partners
• Gilde Investment Management
• IPO
• Netherlands